Sponsored by:
This podcast features Dr. Emma Luckett, whose work at Amsterdam UMC explores how genetics, DNA methylation, and amyloid PET imaging can together reveal the earliest biological signals of Alzheimer’s disease. She discusses the AMYPAD consortium’s large preclinical cohort, her efforts to model amyloid risk using multimodal data and machine learning, and the promise of blood‑based epigenetic markers for improving early detection, trial stratification, and future therapeutic targeting.
This podcast is the third in a series. Read the first Methylation Matters: A New Era in Cardiovascular Risk Prediction with Dr. Charlotte Ling and the second Transforming Breast Cancer Screening: Lessons from a Landmark Colombian Study with Dr. George Busby.
